Literature DB >> 18049888

Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability.

Barbara Ridolfi1, Domenico Genovese, Claudio Argentini, Maria Teresa Maggiorella, Leonardo Sernicola, Stefano Buttò, Fausto Titti, Alessandra Borsetti, Barbara Ensoli.   

Abstract

In a previous study we showed that vaccination with the native Tat protein controlled virus replication in five out of seven monkeys against challenge with the simian human immunodeficiency virus (SHIV)-89.6P cy243 and that this protection correlated with T helper (Th)-1 response and cytotoxic T lymphocyte (CTL) activity. To address the evolution of the SHIV-89.6P cy243 both in control and vaccinated infected monkeys, the sequence of the human immunodeficiency virus (HIV)-1 Tat protein and the C2-V3 Env region of the proviral-DNA-derived clones were analyzed in both control and vaccinated but unprotected animals. We also performed analysis of the T cell epitope using a predictive epitope model taking into consideration the phylogeny of the variants. Our results suggest that even though the viral evolution observed in both groups of monkeys was directed toward variations in the major histocompatibility complex (MHC)-I epitopes, in the control animals it was associated with mutational escape of such epitopes. On the contrary, it is possible that viral evolution in the vaccinated monkeys was linked to mutations that arose to keep high the viral fitness. In the vaccinated animals the reduction of epitope variability, obtained prompting the immune system by vaccination and inducing a specific immunological response against virus, was able to reduce the emergence of escape mutants. Thus the intervention of host's selective forces in driving CTL escape mutants and in modulating viral fitness appeared to be different in the two groups of monkeys. We concluded that in the vaccinated unprotected animals, vaccination with the Tat protein induced a broad antiviral response, as demonstrated by the reduced ability to develop escape mutants, which is known to help in the control of viral replication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18049888     DOI: 10.1007/s11262-007-0179-8

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  28 in total

Review 1.  HIV: current opinion in escapology.

Authors:  Paul Klenerman; Ying Wu; Rodney Phillips
Journal:  Curr Opin Microbiol       Date:  2002-08       Impact factor: 7.934

2.  HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity.

Authors:  Riccardo Gavioli; Eleonora Gallerani; Cinzia Fortini; Marina Fabris; Arianna Bottoni; Alessandro Canella; Angela Bonaccorsi; Mauro Marastoni; Fabiola Micheletti; Aurelio Cafaro; Paola Rimessi; Antonella Caputo; Barbara Ensoli
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

3.  Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope.

Authors:  Fred W Peyerl; Heidi S Bazick; Michael H Newberg; Dan H Barouch; Joseph Sodroski; Norman L Letvin
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution.

Authors:  Bin Li; Adrianne D Gladden; Marcus Altfeld; John M Kaldor; David A Cooper; Anthony D Kelleher; Todd M Allen
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

5.  Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.

Authors:  A Cafaro; A Caputo; C Fracasso; M T Maggiorella; D Goletti; S Baroncelli; M Pace; L Sernicola; M L Koanga-Mogtomo; M Betti; A Borsetti; R Belli; L Akerblom; F Corrias; S Buttò; J Heeney; P Verani; F Titti; B Ensoli
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

6.  Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

Authors:  C A van Baalen; O Pontesilli; R C Huisman; A M Geretti; M R Klein; F de Wolf; F Miedema; R A Gruters; A D Osterhaus
Journal:  J Gen Virol       Date:  1997-08       Impact factor: 3.891

Review 7.  Immunopathogenesis and immunotherapy in AIDS virus infections.

Authors:  Norman L Letvin; Bruce D Walker
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

Review 8.  Gene transcription in HIV infection.

Authors:  Yuntao Wu; Jon W Marsh
Journal:  Microbes Infect       Date:  2003-09       Impact factor: 2.700

9.  Mapping sites of positive selection and amino acid diversification in the HIV genome: an alternative approach to vaccine design?

Authors:  Tulio de Oliveira; Marco Salemi; Michelle Gordon; Anne-Mieke Vandamme; Estrelita Janse van Rensburg; Susan Engelbrecht; Hoosen M Coovadia; Sharon Cassol
Journal:  Genetics       Date:  2004-07       Impact factor: 4.562

10.  Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.

Authors:  Tetsuro Matano; Masahiro Kobayashi; Hiroko Igarashi; Akiko Takeda; Hiromi Nakamura; Munehide Kano; Chie Sugimoto; Kazuyasu Mori; Akihiro Iida; Takahiro Hirata; Mamoru Hasegawa; Takae Yuasa; Masaaki Miyazawa; Yumiko Takahashi; Michio Yasunami; Akinori Kimura; David H O'Connor; David I Watkins; Yoshiyuki Nagai
Journal:  J Exp Med       Date:  2004-06-21       Impact factor: 14.307

View more
  1 in total

1.  The effect of early versus delayed challenge after vaccination in controlling SHIV 89.6P infection.

Authors:  Leslie L Chavez; Miles P Davenport; John W Shiver; Lynda G Tussey; Kara S Cox; Margaret Bachinsky; Fubao Wang; Lingyi Huang; William A Schleif; Mary-Ellen Davies; Aimin Tang; Danilo R Casimiro; Alan S Perelson; Ruy M Ribeiro
Journal:  Virology       Date:  2008-09-14       Impact factor: 3.616

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.